Introduction
Protein C inhibitor (PCI),1 a member of the serpin superfamily, is found in human plasma, urine, and other body fluids (1) (2) (3) . Plasma PCI was first described by Marlar and Griffin as an inhibitor of activated protein C (4) and later purified and characterized by several groups (1, (5) (6) (7) . Urinary PCI, purified and characterized by Stump et al., was initially described as a new urokinase (uPA) inhibitor and therefore named plasminogen activator inhibitor-3 (PAI-3) (8) . Functional and immunologic identity of urinary PAI-3 with PCI from plasma was later shown (9, 10) . Inhibition of both activated protein C and uPA by PCI is stimulated by glycosaminoglycans (9, (11) (12) (13) . Physiological significance of uPA inhibition by PCI in the urinary tract is suggested by the presence of uPA-PCI complexes in normal human urine ( 11) . PCI is also an inhibitor of tissue or urinary kallikrein (14) as well as the structurally homologous enzyme, prostate-specific antigen (3, 15) .
The question of whether at least some of the PCI in urinary uPA-PCI complexes originates in the kidney is raised by the observations that uPA is expressed by human kidney (16, 17) , that inhibition of uPA by PCI is stimulated by glycosaminoglycans (9, 10) , and that glycosaminoglycans that are capable of binding PCI are expressed on the surfaces of epithelial kidney cells grown in culture (2) . The source of the PCI in urine has not been identified previously but has been assumed to originate from plasma. In this study we investigate the expression of PCI by kidney cells both in culture and in situ.
Methods
All reagents were of reagent grade or better. Molecular biology grade reagents were used when available. Polymerase chain reaction (PCR) was performed in a thermal cycler from Perkin-Elmer Cetus Corp. (Norwalk, CT).
cDNA cloning. cDNA for PCI from different sources of RNA was obtained in a three-step procedure that included reverse transcription of total RNA and two rounds of PCR using two sets of specific nested primers designed using the human liver PCI sequence (18) . Total Immunofluorescence microscopy. Renal tissue was obtained from regions of the kidney that were without evidence of tumor invasion from patients nephrectomized for renal carcinoma. Acetone-fixed cryostat sections of normal human kidneys were reacted with rabbit anti-PCI antibody P4 (21 ) , or P4 preincubated with human plasma PCI, and then with tetramethyl-rhodamine-isomer R-conjugated swine anti-rabbit IgG antibody (Dako Corp., Carpinteria, CA). Subsequently, the sections were reacted either with fluorescein isothiocyanate (FITC)-conjugated sheep anti-Tamm-Horsfall protein (Bioproducts for Science, Inc., Indianapolis, IN) or with FITC-conjugated rabbit anti-human FxlA antibody diluted in 1:100 normal rabbit serum to mark the distal or proximal tubules, respectively. The anti-Fx1A antibody was prepared by immunizing rabbits with human FxlA made as described for the rat (23).
The sections were examined with a fluorescence microscope equipped with epiillumination and interference filters to differentiate rhodamine from FITC.
Riboprobe preparation. A full-length human PCI cDNA, obtained as described elsewhere (Radthe, K.-P., J. S. Greengard, J. A. Fernindez, B. Villoutreix, and J. H. Griffin, manuscript submitted for publication), was subcloned into the plasmid pSP73 (Promega Corp., Madison, WI) under the control of transcription promotors SP6 and T7. The plasmid was linearized and utilized as a template for in vitro transcription of radiolabeled antisense or sense riboprobes employing 35S-UTP (> 1,200 Ci/mmol; Amersham Corp., Arlington Heights, IL) and SP6 or T7 RNA polymerase (Promega Corp.), using the reaction conditions recommended by the manufacturer. Templates were removed by digestion with RQ1 DNAse (Promega Corp.) for 15 min at 37TC, and the riboprobes were purified by phenol extraction and ethanol precipitation.
In situ hybridization. Human kidney tissue was obtained after surgery from normal segments of kidneys of patients nephrectomized for renal carcinoma. In situ hybridizations were carried out as described (24) . Before hybridization, the paraffin sections were sequentially treated with xylene (3 x 5 min), with 2 x SSC/10 mM, 2-mercaptoethanol/ 1 mM ethylenediaminetetraacetic acid (EDTA) (1 x 10 min; 1 x SSC = 150 mM NaCl/ 15 mM sodium citrate, pH 7.0), with paraformaldehyde (1 X 10 min, 40C), and with proteinase K (1 jig/ml in 500 mM NaCl/10 mM Tris-HCl, pH 8.0; 1 X 10 min). All incubations and washes were performed at 25°C unless specified otherwise. The slides were then prehybridized for 1-2 h in 100 Al of prehybridization buffer (50% [wt/vol] formamide/0.3 M NaCl/20 mM Tris-HCl, pH 8.0/5 mM EDTA/0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin/10% [wt/vol] dextran sulfate/10 mM dithiothreitol) at 42°C. An additional 20 ,ul of prehybridization buffer containing 2.5 mg/ ml of transfer RNA and -600,000 cpm of the 35S-labeled riboprobe were then added, and the slides were hybridized for 16-18 h at 55°C. After hybridization, the slides were washed with 2x SSC/10 mM 2-mercaptoethanol/l mM EDTA (2 x 10 min), treated with RNAse A (20 /ig/ml in 500 mM NaCl/10 mM Tris-HCl; 1 X 30 min), washed in 2x SSC/10 mM 2-mercaptoethanol/1 mM EDTA (2 x 10 min), and then washed for 2 h in O.1x SSC/10 mM 2-mercaptoethanol/1 mM EDTA at 60°C. Finally, the slides were washed in O.5x SSC (2 X 10 min), dehydrated by immersion in a graded alcohol series containing 0.3 M NH4Ac, dried, coated with NTB2 emulsion (Eastman Kodak Co., Rochester, NY; 1:2 in water), and exposed in the dark at 4°C for 2-6 wk. Slides were developed for 2 min in D19 developer (Eastman Kodak Co.), fixed, washed in water (3 x 5 min), and counterstained with hematoxylin and eosin. Parallel sections were analyzed using a sense probe as control for nonspecific hybridization. No nonspecific hybridization signal was detected in these control hybridizations, even after 6 wk of exposure (data not shown).
Results
The published sequence of human liver PCI cDNA ( 18) predicts an amplification product of 1,221 bp using primers PCI-1 and PCI-10. Fig. 1 shows that the amplification product from human kidney RNA comigrates on an agarose gel with that obtained from human liver RNA. No information was available as to possible pathological conditions, drug administration, or cause of death of the human donors from whom the commercially obtained RNAs were prepared. Therefore, liver and kidney RNAs from healthy rhesus monkeys were also examined to control for such potential complications. Identical amplification products from RNA from rhesus monkey kidney and liver were obtained, using the same primers as for human PCI, indicating that a similar message for PCI is present in rhesus monkey liver and kidney. Human kidney PCI cDNA was further characterized by restriction digestion analysis. Human kidney-and liver-derived PCI cDNAs were digested with restriction endonucleases BclI or StyL. Fig. 2, A In situ hybridization experiments using an antisense PCI RNA probe labeled with 35S showed that PCI RNA is present in human kidney tissue in significant concentrations (Fig. 3 A) . After an exposure time of 2 wk a strong signal for PCI RNA was found in the epithelium of tubular cells. Glomerulus, blood vessels, capsule fat, and medulla were negative. Kidney tissue sections stained with a sense RNA probe of PCI showed no positive signal (Fig. 3 B) . The morphology of the kidney tissue used for in situ hybridization appeared to be normal.
To determine whether the PCI RNA produced in human or rhesus monkey kidney cells is translated, a human kidney cell line (293 cells) and a rhesus monkey kidney cell line (CCL7.1 cells) and tissue sections of human kidneys were examined for the presence of PCI antigen. Fig. 4 shows an immunoblot of conditioned medium from human 293 cells, conditioned medium from rhesus monkey kidney CCL7.1 cells, and semipurified PCI. The samples shown in lanes 2-4 were preincubated with preimmune rabbit IgG, and samples in lanes 5-7 were treated with anti-PCI IgG before electrophoresis. The Fig. 4 could also be detected by monoclonal mouse anti-human PCI antibodies (data not shown).
Immunohistochemistry was used to assess the presence of PCI in kidney. Using immunofluorescence, the anti-PCI antibody was seen to bind to the cytoplasm of a portion (-25%) of tubular cross-sections in the cortex of normal kidney (Fig.   5 ). In addition, diffuse cytoplasmic reactions were seen with a few cells along Bowman Fig. 1 for liver and kidney PCI cDNAs suggest no gross differences exist between them, it is possible that subtle differences arise by means of alternative splicing. This is unlikely to occur in the central portions of PCI RNA, since the gene for human PCI has been sequenced (25) , and no potential alternative exons were observed. However, it is possible that the cloning of the gene overlooked flanking sequences containing alternate exons that substitute sequences at the 5' or 3' ends of the RNA. To eliminate this possibility, PCI cDNA obtained from human kidney was cloned, and 480 bp of sequence were generated from both the 5' and the 3' ends. The sequences were identical to liver-derived PCI cDNAs in each of these regions. Similarly, 5' and 3' sequences obtained from rhesus monkey kidney PCI cDNA were identical to those from rhesus monkey PCI cDNA clones from liver.2 These DNA sequence results indicate that the PCI RNA sequences are identical in liver and kidney from both human and rhesus monkey. To stains for PCI, and the finding of some diffuse cytoplasmic staining along Bowman's capsule might indicate that the proximal tubular regions containing diffuse cytoplasmic PCI were close to the glomerulus. The difference in pattern between the diffuse and punctate staining patterns might relate to production versus reabsorption of the PCI since the larger punctate deposits in some tubules had characteristics sometimes associated with protein reabsorption droplets. However, the finding that PCI antigen and PCI RNA colocalize in tubular kidney cells together with the observation of PCI antigen production by the cultured rhesus monkey kidney cell line and the presence of PCI transcripts in whole kidney total RNA from both species provide evidence for local production of the PCI antigen stained in the tissue slices.
Tubular cells form part of the filtration and reabsorption system of the kidney and are exposed to significant concentrations of uPA present in human urine, which can reach 200 ,sg/ liter (8) . Glycosaminoglycans such as the heparan sulfate side chains on some proteoglycans are an integral component of the glomerular and tubular basement membranes. However, the distribution of heparan sulfate proteoglycans (HSPG) appears to vary among renal basement membranes. The intensity of immunolabeling for HSPG in tubular membranes of the distal tubule is approximately twice that of the glomerular membrane, and that of the proximal tubule is halfway between the two (26) . The localization of PCI within the proximal tubule is significant since glycosaminoglycans stimulate the inhibition of target proteases by PCI (2), and high concentrations of glycosaminoglycans are present within glomerular and tubular basement membranes (26) . Thus, it may be speculated that PCIuPA complex formation may be enhanced in pathologic conditions that result in disruption of the basement membranes with release of HSPG. Indeed, glomerular basement membrane fragments have been identified in the urine of rabbits with antiglomerular membrane antibodies associated with glomerulonephritis (27) , and loss of HSPG from the glomerular basement membrane has been observed in rats with aminonucleoside nephrosis (28) . The net effect of increased PCI efficiency may be limitation of protease-dependent tissue degradation mediated by the metalloproteinases whose activation depends upon plasmin generated by uPA (29) .
Although uPA is produced in the kidney in appreciable concentrations (16, 17, 30) , its physiological role in the renal tract is currently not well characterized. However, it may be speculated that plasmin generation is a key function of this uPA, thereby preventing protein precipitation and clot formation in the renal tubules. uPA plays an important role in the clinical progression of various types of cancers (31, 32) . The presence of the uPA inhibitor, PCI, in an environment that is exposed to uPA suggests that PCI may play a protective role in normal kidney tissue, blocking the profibrinolytic and mitogenic activity of uPA (33) , while directing uPA activity towards the lumen of the filtration system where proteolysis is required to maintain an unrestricted flow of liquids. The current results have significance for understanding the physiology of the human urinary tract and support the idea that uPA-PCI complexes found in human urine are locally produced in the kidney. The data imply that ongoing control of fibrinolytic activity is a natural requirement of the kidney milieu. Any pathological process that alters the fibrinolytic balance could potentially have deleterious effects on the kidney function, as it is known that plasma levels of the zymogen of another target protease of PCI, protein C, are significantly decreased in patients with chronic renal insufficiency and uremia (34, 35) . In view of data showing that uPA has a direct mitogenic effect on primary cultures of renal cells (33) , the role of its regulator, PCI, needs to be evaluated in the progression of renal cancer.
This study opens a new area of investigation into the pathophysiology of various kidney conditions.
